The FY2025 (Dec) proxy of Kiniksa Pharmaceuticals International names 20 peer companies for pay. Among Kiniksa Pharmaceuticals International and these peers, CEO pay was 4th highest of 10 and total shareholder return was the highest of 10.
4th highest of 10in Kiniksa Pharmaceuticals International and its pay peers, FY2025 (Dec) by CEO pay:
$1.7M$15.5M
1st highest of 10in Kiniksa Pharmaceuticals International and its pay peers, FY2025 (Dec) by total shareholder return:
$17$233
Pay peer group, FY2025 (Dec) proxy
| Supernus Pharmaceuticals | ||
| BridgeBio Pharma | ||
| Ultragenyx Pharmaceutical | ||
| Travere Therapeutics | ||
| Harmony Biosciences Holdings | ||
| Ardelyx | ||
| Arcutis Biotherapeutics | ||
| Agios Pharmaceuticals | ||
| Collegium Pharmaceutical | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Therapeutics | Not disclosed | Not disclosed |
| Apellis Pharmaceuticals | Not disclosed | Not disclosed |
| Biocryst Pharmaceuticals | Not disclosed | Not disclosed |
| Blueprint Medicines | Not disclosed | Not disclosed |
| Corcept Therapeutics | Not disclosed | Not disclosed |
| Ironwood Pharmaceuticals | Not disclosed | Not disclosed |
| MacroGenics | Not disclosed | Not disclosed |
| Rhythm Pharmaceuticals | Not disclosed | Not disclosed |
| Sage Therapeutics | Not disclosed | Not disclosed |
| Vericel | Not disclosed | Not disclosed |
20 companies
Changes by year
FY2025 (Dec) proxy
- AddedAcadia Pharmaceuticalspay peer groupdue to their overall fit relative to the selected peer criteria
- AddedApellis Pharmaceuticalspay peer groupdue to their overall fit relative to the selected peer criteria
- AddedArcutis Biotherapeuticspay peer groupdue to their overall fit relative to the selected peer criteria
- AddedArdelyxpay peer groupdue to their overall fit relative to the selected peer criteria
- AddedHarmony Biosciences Holdingspay peer groupdue to their overall fit relative to the selected peer criteria
- AddedSupernus Pharmaceuticalspay peer groupdue to their overall fit relative to the selected peer criteria
- AddedVericelpay peer groupdue to their overall fit relative to the selected peer criteria
- RemovedBluebird Biopay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
- RemovedDeciphera Pharmaceuticalspay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
- RemovedImmunoGenpay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
- RemovedINSMEDpay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
- RemovedIntercept Pharmaceuticalspay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
- RemovedKaryopharm Therapeuticspay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
- RemovedRigel Pharmaceuticalspay peer groupIn updating the compensation peer group for 2025, the Compensation Committee removed Deciphera Pharmaceuticals, ImmunoGen, Intercept Pharmaceuticals, Bluebird Bio, Insmed, Karyopharm Therapeutics and Rigel Pharmaceuticals as they no longer fit within the peer selection criteria with respect to market capitalization and/or revenue, as applicable
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.